Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Allovir

Allovir
2013 FOUNDED
PRIVATE STATUS
Series B LATEST DEAL TYPE
$121M LATEST DEAL AMOUNT
13 INVESTORS
Description

Developer of thymocytes cell therapies designed to treat viral infections. The company's thymocytes cell therapies eliminates deadly viral infections in immune compromised patients by using virus killing thymocytes cells and offers a personalized product prepared from the HSCT donor that can be used to prevent viral infections, enabling doctors to treat viral infections and helps patients to recover the same.

Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • 2925 Richmond Avenue
  • Suite 1200, Kirby Grove
  • Houston, TX 77098
  • United States

+1 (936) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Allovir’s full profile, request a free trial.

Allovir Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Later Stage VC (Series B) 21-May-2019 $121M 00000 00000 Completed Clinical Trials - Phase 2
7. Later Stage VC 18-Dec-2018 00.00 000.00 00000 Completed Generating Revenue
6. Early Stage VC 02-Oct-2018 0000 0000 Completed Clinical Trials - Phase 2
5. Grant 21-Aug-2017 00.000 Completed Startup
4. Grant 05-Jul-2017 00.000 Completed Startup
3. Grant 01-Jan-2017 00000 Completed Startup
2. Accelerator/Incubator 02-Mar-2016 Completed Startup
1. Angel (individual) 01-Jan-2014 Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Allovir Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series B 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series A4 0,000,000 00.000000 00 00.0 00.0 00 00.0 0.00
Series A3 00,000,000 00.000000 00 00.0 00.0 00 00.0 00.000
Series A2 20,000,000 $0.000100 8% $1.5 $1.5 1x $1.5 22.29%
Series A1 20,000,000 $0.000100 8% $1.5 $1.5 1x $1.5 22.29%
To view this company’s complete Cap Table, request access »

Allovir Investors (13)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
EcoR1 Capital Hedge Fund Minority 000 0000 000000 0
F2 Ventures Venture Capital Minority 000 0000 000000 0
Fidelity Management & Research Asset Manager Minority 000 0000 000000 0
Gilead Sciences Corporation Minority 000 0000 000000 0
Redmile Group Hedge Fund Minority 000 0000 000000 0
You’re viewing 5 of 13 investors. Get the full list »

Allovir Executive Team (9)

Name Title Board
Seat
Contact
Info
David Hallal Chief Executive Officer & Chairman
Vikas Sinha President, Chief Financial Officer & Board Member
Ann Leen Ph.D Chief Scientific Officer & Co-Founder
Juan Vera MD Co-Founder, Chief Product Development Officer & Board Member
Helen Heslop MD Co-Founder & Advisor

1 Former Executive

You’re viewing 5 of 9 executives. Get the full list »

Allovir Board Members (7)

Name Representing Role Since Contact
Info
Ansbert Gadicke Allovir Board Member 000 0000
David Hallal Allovir Chief Executive Officer & Chairman 000 0000
John Wilson Allovir Board Member 000 0000
Juan Vera MD Allovir Co-Founder, Chief Product Development Officer & Board Member 000 0000
Malcolm Brenner MD Allovir Advisor & Board Member 000 0000
You’re viewing 5 of 7 board members. Get the full list »